TrialClinical pharmacology and therapeutics2022

Mobocertinib Dose Rationale in Patients with Metastatic NSCLC with EGFR Exon 20 Insertions: Exposure-Response Analyses of a Pivotal Phase I/II Study.

Neeraj Gupta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.